pardoprunox
Small moleculeexperimental
Pardoprunox is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
6
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00134251)
Timeline
Indications
Studied for
Mechanism of action
HTR1A agonist
- Dopamine receptors; D2 & D3PARTIAL AGONIST
Dopamine receptors; D2 & D3 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2cccc3[nH]c(=O)oc23)CC1- Mol. weight
- 233.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPardoprunox ↗
- ChEMBLCHEMBL2103832 ↗
Also known as
- 2(3h)-benzoxazolone, 7-(4-methyl-1-piperazinyl)-monohydrochloride
- du-126891
- du-126891
- pardoprunox
- pardoprunox
- pardoprunox
- pardoprunox
- pardoprunox
- slv308
- slv308
- slv-308
- slv-308
- slv-308
- sme-308
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00903838 | Phase 2 | Sep 1, 2009 | Abbott |
| NCT00335374 | Phase 3 | Aug 1, 2007 | Solvay |
| NCT00407095 | Phase 3 | Aug 1, 2007 | Abbott, Solvay |
| NCT00332917 | Phase 3 | Feb 1, 2007 | Solvay |
| NCT00335166 | Phase 3 | Nov 1, 2006 | Solvay |
| NCT00269516 | Phase 3 | Jun 1, 2006 | Solvay |
| NCT00134251 | Phase 3 | Oct 1, 2005 | Solvay |
Showing 7 of 7 trials
Page 1 / 1